HC Stocks Watchful! Johnson & Johnson (JNJ), Merck& Co. (MRK)

Shares of Johnson & Johnson (NYSE:JNJ) ended Friday session in red amid volatile trading. The shares closed down -0.37 points or -0.32% at $115.33 with 8,813,324 shares getting traded. Post opening the session at $115.82, the shares hit an intraday low of $114.57 and an intraday high of $115.91 and the price vacillated in this range throughout the day. The company has a market cap of $314.52 billion and the numbers of outstanding shares have been calculated to be 2.74 billion shares.

Johnson & Johnson (JNJ) announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2016 of $0.80 per share on the company’s common stock.  The dividend is payable on December 6, 2016 to shareholders of record at the close of business on November 22, 2016. The ex-dividend date is November 18, 2016.

Shares of Merck& Co., Inc. (NYSE:MRK)  ended Friday session in red amid volatile trading. The shares closed down -2.45 points or -4.00% at $58.84 with 20,358,443 shares getting traded. Post opening the session at $61.02, the shares hit an intraday low of $58.45 and an intraday high of $61.07 and the price vacillated in this range throughout the day. The company has a market cap of $156.20 billion and the numbers of outstanding shares have been calculated to be 2.77 billion shares.

Merck& Co., Inc. (MRK)  announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. With this new indication, KEYTRUDA is now the only anti-PD-1 therapy to be approved in the first-line treatment setting for these patients. In addition, the FDA approved a labeling update to include data from KEYNOTE-010 in the second-line or greater treatment setting for patients with metastatic NSCLC whose tumors express PD-L1 (TPS of one percent or more) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. In metastatic NSCLC, KEYTRUDA is approved for use at a fixed dose of 200 mg every three weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *